Calypso Biotech Announces First Celiac Disease Patient Receiving Phase 1b Trial of Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 and Series A Extension to € 28M

AMSTERDAM – (COMMERCIAL THREAD) – Calypso Biotech, a Leader in the Development of Targeted Interleukin-15 (IL-15) Therapies, Today Announces Dosing Completion of the First Patient with Celiac Disease in the Phase Clinical Trial 1 of CALY-002, a novel humanized neutralizing IL-15 monoclonal antibody. The ongoing clinical study of CALY-002 includes a single ascending dose in healthy volunteers, now successfully completed, as well as an ascending dose of cohorts of patients with celiac disease and eosinophilic esophagitis, two indications with significant unmet medical need where IL-15 plays a critical role.

The company is now expanding senior clinical leadership to reflect this important transition to clinical evaluation. Dr Jos GA Houbiers MD, PhD joined Calypso Biotech as Chief Medical Officer on June 1st. Dr Houbiers brings to Calypso Biotech over 25 years of clinical pharmaceutical development experience for large pharmaceutical and biotechnology companies, where he has implemented medical and clinical development strategies, creative trial design and oversight. comprehensive medical safety in all therapeutic areas including immunology, urology and pain. He most recently served as Chief Medical Officer at Summit Therapeutics. Dr Houbiers obtained his MD from Leiden University Medical Center and MD (immunology) and MD from Leiden University.

Reflecting this exciting clinical progression, Calypso Biotech raised an additional € 8 million in the 2019 Series A round, bringing its total Series A funding to € 28 million from new and existing investors. Fountain HealthCare Partners joins the renowned syndicate of Gilde Healthcare, Inkef Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and the company’s founding investor, M Ventures. Dr Ena Prosser from the Fountain’s Dublin (Ireland) office has also joined the Calypso Biotech Board of Directors. active, and develop a strong translational package to support the development of CALY-002 in other indications of autoimmune diseases.

Alain Vicari, CEO of Calypso Biotech, said: “We are delighted to welcome Dr Jos Houbiers to the team and to announce the extension of the Series A syndicate with Fountain Healthcare Partners. This further validates our ability to attract high quality investors and bodes well for our future fundraising campaign. These funds will accelerate the development of CALY-002 and bring us closer to proposing a new paradigm for treating autoimmune diseases to patients in need.

About Calypso Biotech BV

Calypso Biotech BV is a privately held biotechnology company focused on the research and development of new biologics to address unmet medical needs in immunological diseases, with unique expertise in IL-15 biology. IL-15 controls the immune pathways critically involved in the onset and maintenance of disease, as well as in tissue destruction, in addition to its broad effect on inflammation. Calypso’s approach offers significant advantages over traditional interventional cytokine therapies and could provide long-lasting disease-modifying effects unheard of in multiple autoimmune diseases. Calypso Biotech is a healthcare spin-off company of Merck KGaA and is headquartered in Amsterdam, the Netherlands, with offices and laboratories in Geneva, Switzerland. The company raised its initial Series A funding in 2018 with Gilde Healthcare, Inkef Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and the company’s founding investor, M Venture; Fountain Healthcare Partners joined this syndicate in 2021. For more information, visit www.calypsobiotech.com.

About Fountain Healthcare Partners

Fountain Healthcare Partners is a life sciences venture capital fund with offices in Dublin and New York. Founded in 2008, Fountain is Ireland’s largest dedicated life sciences venture capital fund with over € 300 million under management. Fountain invests in entrepreneurs and businesses with disruptive technologies or products that have a clear pharmaco-economic advantage and a defined path to commercialization, value enhancement and exit. Fountain generally directs or co-directs its investments and has entered into private and public agreements with start-ups, business spin-outs and turnaround situations. The three directors of Fountain Healthcare Partners Fund III, Manus Rogan, Aidan King and Ena Prosser, bring to investors more than 70 years of collective experience in the pharmaceutical industry, corporate venture capital and venture capital over several investment and market cycles. For more information www.fh-partners.com.

About Gilde Santé

Gilde Healthcare is a European investor specializing in healthcare which manages 1 billion euros ($ 1.2 billion) through two fund strategies: venture capital and development capital and private equity. Gilde Healthcare’s venture capital and growth fund invests in healthcare technologies and therapeutics. Venture capital and growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable, lower-mid-sized European healthcare companies, with a focus on the Benelux and the DACH region. The private equity fund targets healthcare providers, medical product suppliers and service providers in the healthcare market. For more information www.gildehealthcare.com.

About INKEF Capital

INKEF Capital is an Amsterdam-based venture capital firm focused on long-term collaboration and active support of innovative technology companies. INKEF Capital was founded in 2010 by the Dutch pension fund ABP and with 500 million euros under management is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportunities in healthcare, technology, IT / new media, and financial technology. For more information www.inkefcapital.com.

About Johnson & Johnson Innovation – JJDC, Inc.

Johnson & Johnson Innovation – JJDC, Inc. is the venture capital arm of Johnson & Johnson which has been investing since 1973 in the fields of medical devices, diagnostics, pharmaceuticals and consumer health. JJDC’s goal is to create opportunities that meet the strategic needs of its operating subsidiaries while providing visibility into innovative emerging technologies, companies and business models. JJDC invests in businesses across the continuum, from seed investments to the advanced stages of serial business management. For more information www.jjdc.com.

About M Ventures

M Ventures is the strategic corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to have a significant impact on the core business areas of the company. From its headquarters in Amsterdam and offices in the United States and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures plays an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation into business success. M Ventures has a strong focus on early stage investments and business creation, including the creation of spin-offs to leverage the company’s science and technology base. For more information www.m-ventures.com.

Source link

About Perry Perrie

Perry Perrie

Check Also

UNM is part of $ 15 million NSF I-Corps Hub for Economic Development: UNM Newsroom

The National Science Foundation has announced the creation of five I-Corps Hubs across the country …

Leave a Reply

Your email address will not be published. Required fields are marked *